tiprankstipranks
Trending News
More News >
Nephros Inc (NEPH)
NASDAQ:NEPH
Advertisement

Nephros (NEPH) AI Stock Analysis

Compare
77 Followers

Top Page

NEPH

Nephros

(NASDAQ:NEPH)

Rating:61Neutral
Price Target:
$4.00
▲(16.28%Upside)
Nephros is demonstrating positive trends in financial performance and technical analysis, with improving profitability and bullish stock momentum. However, the high P/E ratio indicates a potential overvaluation, suggesting caution. The company's financial stability is a strong positive, but challenges in revenue growth and cash flow management remain.
Positive Factors
Customer Expansion
NEPH added roughly 100 new Active Customer Sites, increasing its customer base to approximately 1,600, demonstrating growth in customer reach.
Financial Performance
NEPH reported revenue, gross margin, and GAAP EPS above both consensus and analyst estimates, indicating strong financial performance.
Product Innovation
The launch of the S100 In-Line microfilter provides enhanced installation flexibility, promoting broader use in low-pressure plumbing applications.
Negative Factors
Cash Position
Despite having no debt, NEPH's cash and equivalents stand at $4.1M, which could be a concern for liquidity management.
Market Valuation
Nephros trades at a lower EV/revenue multiple compared to peers, suggesting the market may undervalue its potential growth.

Nephros (NEPH) vs. SPDR S&P 500 ETF (SPY)

Nephros Business Overview & Revenue Model

Company DescriptionNephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
How the Company Makes MoneyNephros generates revenue through the sale of its water filtration and purification products. The company's primary revenue streams include direct sales to healthcare facilities, dialysis centers, and commercial entities. Nephros also engages in partnerships and distribution agreements to expand its market reach and enhance product availability. Revenue is further supported by repeat sales of consumable filter cartridges, which require regular replacement to maintain optimal filtration performance. The company's focus on innovation and quality positions it to effectively serve industries where water purity is critical.

Nephros Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q3-2024)
|
% Change Since: 72.86%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Neutral
While Nephros achieved its first profitable quarter and improved its gross margin and adjusted EBITDA, the company faced a decline in year-over-year revenue and cash reserves, along with regional underperformance challenges. Despite these issues, strategic initiatives and cost management have positioned Nephros for potential future growth.
Q3-2024 Updates
Positive Updates
First Profitable Quarter Achieved
Nephros reported its first profitable quarter with a net income of $0.2 million compared to a net loss of $0.2 million in Q3 of the previous year.
Improved Gross Margin
Gross margin increased to 61% from 59% in Q3 2023, reflecting improved terms with the largest supplier.
Significant Improvement in Adjusted EBITDA
Adjusted EBITDA for Q3 was $295,000, a substantial increase from $11,000 in the same quarter last year.
SG&A Expenses Reduction
SG&A expenses were reduced by 19% to $1.7 million from $2.1 million in Q3 2023 due to lower stock compensation and bonus accruals.
Strategic Advancements and Future Growth
Nephros is expanding into new markets such as sterile processing, laboratories, and dental practices and is exploring partnerships for solutions to nano and microplastic contaminations.
Negative Updates
Decline in Year-Over-Year Revenue
Q3 net revenue was $3.5 million, a 6% decline compared to Q3 2023, mainly due to underperformance in programmatic revenue.
Cash and Cash Equivalents Decline
Cash and cash equivalents decreased to $2.5 million from $4.3 million at the end of 2023, primarily due to operating losses in the first half of 2024.
Underperformance in Specific Regions
The company faced challenges in specific regions, with some larger accounts showing slower order patterns.
Company Guidance
During the Nephros Q3 2024 earnings call, the company reported achieving its first profitable quarter since inception, with a net income of $0.2 million compared to a net loss of $0.2 million in Q3 2023. Net revenue for the quarter was $3.5 million, up 8% from Q2 2024 but down 6% from Q3 2023. The gross margin improved to 61% from 59% in Q3 2023, driven by better terms with a major supplier. Adjusted EBITDA for the quarter was $295,000, a significant improvement from $11,000 in the previous year. SG&A expenses were reduced by 19% to $1.7 million, contributing to the positive financial outcome. The company highlighted strategic advancements, such as the introduction of digital support tools for filter installation and plans to expand into new markets like sterile processing and dental practices. Cash and cash equivalents stood at $2.5 million as of September 30, 2024, down from $4.3 million at the end of 2023, primarily due to earlier operating losses and inventory investments.

Nephros Financial Statement Overview

Summary
Nephros is on a path to profitability with improving net income and gross margins. The company's low leverage and strong equity position provide financial stability. However, challenges remain in generating consistent revenue growth and positive cash flow, necessitating a focus on operational efficiency and cash management.
Income Statement
62
Positive
Nephros has shown improvements in net income, transitioning from a loss in previous years to a profit in the most recent year. The gross profit margin increased from 57% to 62%, indicating improved cost efficiency. However, revenue has slightly decreased over the past year, and EBIT and EBITDA margins remain thin, suggesting challenges in operational efficiency.
Balance Sheet
70
Positive
The balance sheet reflects a stable equity position with a debt-to-equity ratio of 0.16, indicating low leverage. The equity ratio remains strong at 76.6%, reflecting a solid capital structure. Despite declining total assets, the company's liabilities have decreased, enhancing financial stability.
Cash Flow
55
Neutral
Cash flow from operations turned negative this year, reversing from a positive position last year. Free cash flow growth was negative, indicating a need for better cash management. The operating cash flow to net income ratio is unfavorable, suggesting room for improvement in cash generation relative to profitability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.16M14.24M9.97M10.22M8.56M
Gross Profit8.72M8.40M4.73M5.63M4.91M
EBITDA227.00K-1.36M-3.69M-2.49M-4.21M
Net Income74.00K-1.57M-4.55M-4.11M-4.77M
Balance Sheet
Total Assets11.21M11.86M11.00M17.65M18.51M
Cash, Cash Equivalents and Short-Term Investments3.76M4.31M3.63M6.97M8.25M
Total Debt1.41M1.84M1.09M1.12M2.17M
Total Liabilities2.63M3.50M2.12M2.90M2.94M
Stockholders Equity8.59M8.36M5.59M11.70M12.52M
Cash Flow
Free Cash Flow-547.00K752.00K-3.37M-1.45M-7.14M
Operating Cash Flow-492.00K827.00K-3.23M-1.42M-6.90M
Investing Cash Flow-50.00K-75.00K-137.00K-85.00K-239.00K
Financing Cash Flow-5.00K-79.00K34.00K237.00K11.22M

Nephros Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price3.44
Price Trends
50DMA
3.40
Positive
100DMA
2.59
Positive
200DMA
2.06
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
47.10
Neutral
STOCH
20.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEPH, the sentiment is Neutral. The current price of 3.44 is below the 20-day moving average (MA) of 3.80, above the 50-day MA of 3.40, and above the 200-day MA of 2.06, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NEPH.

Nephros Risk Analysis

Nephros disclosed 25 risk factors in its most recent earnings report. Nephros reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Nephros Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$36.47M45.569.17%10.34%
56
Neutral
$37.56M-47.37%-9.20%-232.02%
53
Neutral
$25.20M-138.80%-14.41%-549.88%
52
Neutral
$21.11M-25.89%-16.05%-195.28%
50
Neutral
AU$2.62B3.32-57.47%2.40%36.73%13.67%
40
Neutral
$29.77M-239.87%61.97%-6.89%
40
Underperform
$46.69M-88.36%-9.13%30.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NEPH
Nephros
3.44
1.25
57.08%
HBIO
Harvard Bioscience
0.57
-2.73
-82.73%
RVP
Retractable Technologies
0.70
-0.43
-38.05%
MLSS
Milestone Scientific
0.60
-0.44
-42.31%
POCI
Precision Optics Corporation
4.90
-1.16
-19.14%
FEMY
Femasys
0.92
-0.22
-19.30%

Nephros Corporate Events

Executive/Board ChangesShareholder Meetings
Nephros Holds Annual Stockholders Meeting June 2025
Neutral
Jun 16, 2025

On June 16, 2025, Nephros, Inc. conducted its Annual Meeting of Stockholders where several key decisions were made. Stockholders elected Lisa Nettis to the Board of Directors for a term ending in 2028, ratified Baker Tilly US, LLP as the independent public accounting firm for 2025, and approved the executive officers’ compensation on a non-binding basis. These decisions reflect the company’s ongoing governance and operational strategies.

The most recent analyst rating on (NEPH) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Nephros stock, see the NEPH Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Nephros Board Member Alisa Lask to Step Down
Neutral
Apr 28, 2025

On April 23, 2025, Alisa Lask informed Nephros, Inc. that she will not seek re-election to the Board of Directors at the upcoming annual stockholders meeting on June 16, 2025. Her decision is not due to any disagreements with the company’s operations or policies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025